Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bahige Asaker

Internal Medicine Brockton, MA Doctor of Osteopathy

NPI 1104927102 CMS profile 50427

1020 Pleasant Street, Brockton, MA 02301

Open in the dashboard

General payments

$14,385

774 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bahige Asaker of Brockton, MA is reported in the CMS Open Payments database as having received $14,385 across 774 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,140 98
2024 General $2,084 105
2023 General $1,918 89
2022 General $2,257 118
2021 General $2,400 144
2020 General $935 54
2019 General $2,651 166

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bahige Asaker
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Bahige Asaker were reported at $2,140. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Bahige Asaker Internal Medicine median Middle half National median
2019 $2,651 $159 $48–$570 $163
2020 $935 $119 $33–$402 $114
2021 $2,400 $135 $37–$521 $132
2022 $2,257 $141 $42–$496 $149
2023 $1,918 $149 $45–$519 $160
2024 $2,084 $154 $47–$537 $164
2025 $2,140 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,550 66 payments
  2. AbbVie, Inc. $1,276 68 payments
  3. Pfizer Inc. $1,126 75 payments
  4. Sunovion Pharmaceuticals Inc. $863 43 payments
  5. Novartis Pharmaceuticals Corporation $752 47 payments
  6. Lilly USA, LLC $716 41 payments
  7. Novo Nordisk Inc $623 40 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $473 21 payments
  9. Janssen Pharmaceuticals, Inc $463 26 payments
  10. Mylan Specialty L.P. $451 26 payments
  11. Other $6,091 321 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,346 771 payments
  2. Education $40 3 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR $1,056 52 payments
  2. FARXIGA $950 36 payments
  3. APTIOM $540 27 payments
  4. GEMTESA $481 24 payments
  5. ENTRESTO $472 31 payments
  6. XARELTO $432 24 payments
  7. YUPELRI $432 25 payments
  8. SPIRIVA RESPIMAT $353 17 payments
  9. Ozempic $352 23 payments
  10. INVOKANA $346 18 payments
  11. Other $13,217 745 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 257 drugs

Part D claims

34,127

Median for Internal Medicine: 777

Drug cost

$1,939,284

Median for Internal Medicine: $73,373

Branded share of claims

17.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,059 $335,892
Jardiance Empagliflozin Brand 346 $209,449
Januvia Sitagliptin Phosphate Brand 315 $163,933
Ozempic Semaglutide Brand 144 $139,188
Trulicity Dulaglutide Brand 98 $114,489
Xarelto Rivaroxaban Brand 242 $85,637
Farxiga Dapagliflozin Propanediol Brand 94 $81,255
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 74 $48,736
Dovato Dolutegravir Sodium/Lamivudine Brand 26 $37,496
Mounjaro Tirzepatide Brand 37 $36,202

The 10 drugs with the highest cost, of 257 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$233,018

Of which drugs: $9,474

Medicare patients

595

Average age 74

Services billed

3,698

280 women, 315 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 47%
Arthritis 46%
Depression 41%
COPD 31%
Ischemic heart disease 30%
Alzheimer's or dementia 28%
Heart failure 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 41 41 $5,363
Influenza vaccine, trivalent derived from cell cultures 90661 Office 112 112 $4,044

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
$206 94 —
LEQVIO
$179 — —
REXULTI
$159 — —
VOQUEZNA
$138 — —
MOUNJARO
$114 37 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

774 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record